Core Viewpoint - First Solar, Inc. is expected to report second-quarter 2025 results on July 31, 2025, after market close, with a negative earnings surprise of 22.00% in the last quarter and a four-quarter average negative earnings surprise of 6.94% [1] Factors Impacting Results - Global solar energy demand is steadily improving, driven by increasing energy consumption, declining installation costs, and heightened clean energy awareness, which is expected to boost sales volume for First Solar's products [2] - Solid revenue growth expectations are supported by a high mix of modules sold from U.S. factories that qualify for Section 45X tax credits, likely enhancing quarterly earnings growth [3] - However, lower capacity utilization and throughput at Malaysia and Vietnam factories, due to anticipated reduced demand for modules from newly imposed U.S. tariffs, may negatively impact revenues and earnings [4] - A shift in sales mix is anticipated, with more modules directed to the lower-priced Indian market instead of the U.S., which may also hurt top and bottom-line performance [5] - High module production costs in the U.S. and underutilization charges from lower-than-full production capacity in Asia are likely to affect overall bottom-line performance [6] Q2 Estimates - The Zacks Consensus Estimate for FSLR's second-quarter sales is $1.03 billion, indicating year-over-year growth of 1.9% [7] - The consensus estimate for earnings per share is $2.68, reflecting a year-over-year decline of 17.5% [7] Earnings Prediction Model - The current model does not predict an earnings beat for First Solar, with an Earnings ESP of -5.23% and a Zacks Rank of 3 (Hold) [8][10] Summary of Revenue Influences - Q2 revenues may rise due to strong solar demand and increased sales of U.S.-made modules, while new tariffs likely reduced Southeast Asia output, shifting module sales to lower-priced markets like India [9] - Higher U.S. production costs and factory underuse in Asia may weigh on FSLR's Q2 earnings performance [9]

Company Overview - Regeneron is expected to report a year-over-year decline in earnings, with a projected EPS of $8.15, reflecting a decrease of 29.5% compared to the previous year [3] - Revenues are anticipated to be $3.34 billion, down 5.7% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 6.49% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Regeneron is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +7.62% [12] Earnings Surprise Potential - Regeneron has a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12] - Historically, Regeneron has beaten consensus EPS estimates three out of the last four quarters [14] Market Expectations - The stock price may increase if the actual earnings exceed expectations in the upcoming report, scheduled for August 1 [2] - Conversely, if the earnings miss expectations, the stock may decline [2] Industry Context - Alnylam Pharmaceuticals, another player in the biomedical sector, is expected to report a loss of $0.03 per share, indicating a significant year-over-year decline of 105.4% [18] - Alnylam's revenues are projected to be $671.11 million, up 1.7% from the previous year, with a substantial positive Earnings ESP of +831.25% [19][20]

Core Viewpoint - T. Rowe Price (TROW) is anticipated to report a year-over-year decline in earnings due to lower revenues, with the consensus estimate indicating a potential impact on its near-term stock price [1][3]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $2.10 per share, reflecting a year-over-year decrease of 7.1%, and revenues are projected to be $1.71 billion, down 1.4% from the previous year [3]. - A positive movement in stock price may occur if the actual earnings exceed expectations, while a miss could lead to a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised 9.62% higher in the last 30 days, indicating a collective reassessment by analysts [4]. - The Most Accurate Estimate for T. Rowe is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.99%, suggesting a bullish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy) [10]. - T. Rowe currently holds a Zacks Rank of 1, enhancing the likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, T. Rowe exceeded the expected earnings of $2.09 per share by delivering $2.23, resulting in a surprise of +6.70% [13]. - Over the past four quarters, T. Rowe has beaten consensus EPS estimates three times [14]. Industry Context - In the broader financial services sector, Blue Owl Capital Inc. is expected to report earnings of $0.21 per share, reflecting a year-over-year increase of 10.5%, with revenues projected to rise by 22.5% [18][19]. - Blue Owl Capital's Earnings ESP is -0.82%, combined with a Zacks Rank of 3 (Hold), making it challenging to predict an earnings beat [20].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Linde, with expectations of higher revenues impacting stock price based on actual results compared to estimates [1][2]. Company Summary - Linde is expected to report quarterly earnings of $4.03 per share, reflecting a year-over-year increase of +4.7% [3]. - Revenue projections stand at $8.35 billion, indicating a 1% increase from the previous year [3]. - The consensus EPS estimate has been revised down by 0.05% over the last 30 days, suggesting a slight reassessment by analysts [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Linde is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.43%, indicating a bullish outlook from analysts [12]. - Linde holds a Zacks Rank of 3, suggesting a moderate expectation of beating the consensus EPS estimate [12]. - Historically, Linde has surpassed consensus EPS estimates in the last four quarters, with a recent surprise of +0.51% [13][14]. Industry Context - In the Zacks Chemical - Specialty industry, Quaker Chemical is expected to report earnings of $1.82 per share, reflecting a year-over-year decrease of -14.6% [18]. - Quaker Chemical's revenue is projected at $463.19 million, down 0.1% from the previous year, with a recent EPS estimate revision of -1.2% [19]. - Quaker Chemical has an Earnings ESP of -1.84% and a Zacks Rank of 3, making it challenging to predict an earnings beat [20].

Core Viewpoint - Newell Brands (NWL) is expected to report a year-over-year decline in earnings due to lower revenues, with the consensus outlook being crucial for assessing the company's earnings picture [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to show earnings of $0.24 per share, reflecting a decline of 33.3% year-over-year, and revenues are projected to be $1.94 billion, down 4.4% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.64% higher in the last 30 days, indicating a slight bullish sentiment among analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - Newell Brands has a positive Earnings ESP of +6.28%, suggesting that analysts have recently become more optimistic about the company's earnings, which may lead to beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Newell Brands was expected to post a loss of $0.07 per share but instead reported a loss of -$0.01, resulting in a surprise of +85.71%. Over the last four quarters, the company has beaten consensus EPS estimates three times [13][14]. Investment Considerations - While Newell Brands appears to be a compelling earnings-beat candidate, investors should consider other factors that may influence stock performance beyond just earnings results [15][17].

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) is expected to report a year-over-year increase in earnings and revenues for the quarter ended June 2025, with a consensus EPS estimate of $0.19, reflecting a 90% increase, and revenues projected at $2.99 billion, up 9.4% from the previous year [1][3]. Earnings Expectations - The stock price may rise if the actual earnings exceed expectations in the upcoming report, scheduled for August 1, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 3.68% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative Earnings ESP reading indicates the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [9][10]. - For BrightSpring, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -8.11%, suggesting a bearish outlook [12]. Historical Performance - BrightSpring has beaten consensus EPS estimates in two out of the last four quarters, with a notable surprise of +137.50% in the last reported quarter [14][15]. Industry Comparison - CVS Health, a competitor in the Zacks Medical Services industry, is expected to report an EPS of $1.47, reflecting a year-over-year decrease of 19.7%, with revenues projected at $93.72 billion, up 2.7% [20]. - CVS Health has a positive Earnings ESP of +2.06% and a Zacks Rank of 2, indicating a likely earnings beat, having surpassed consensus EPS estimates in the last four quarters [20][21].

Core Viewpoint - PG&E Corporation (PCG) is set to report its second-quarter 2025 results on July 31, with expectations of revenue and earnings growth despite a previous earnings surprise of -5.71% in the last quarter [1][9]. Factors Influencing Q2 Results - Warmer-than-normal temperatures in PCG's service territories likely increased electricity demand for cooling, positively impacting revenues [2]. - Strong rate-based growth and favorable outcomes from previously approved general rate case filings are expected to contribute to revenue performance [2]. - Efforts to reduce non-fuel operations and maintenance (O&M) expenses may enhance earnings for the quarter [3]. Q2 Expectations - The Zacks Consensus Estimate for sales is $6.37 billion, reflecting a year-over-year growth of 6.4% [4]. - The consensus estimate for earnings is 33 cents per share, indicating a year-over-year increase of 6.5% [4]. Earnings Prediction Insights - The current Earnings ESP for PCG is 0.00%, making it challenging to predict an earnings surprise despite anticipated sales growth [5][9]. - PCG holds a Zacks Rank of 3, suggesting a neutral outlook [6]. Industry Comparisons - American Electric Power (AEP) is expected to report on July 30, with an Earnings ESP of +10.63% and a Zacks Rank of 3 [7]. - IDACORP Inc. (IDA) is also reporting on July 31, with an Earnings ESP of +4.55% and a Zacks Rank of 3 [10]. - Xcel Energy Inc. (XEL) is scheduled for July 31, with an Earnings ESP of +1.76% and a Zacks Rank of 3 [11].

Core Insights - Ponce Financial (PDLB) reported quarterly earnings of $0.25 per share, exceeding the Zacks Consensus Estimate of $0.17 per share, and showing an increase from $0.14 per share a year ago, resulting in an earnings surprise of +47.06% [1] - The company achieved revenues of $26.49 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.28% and up from $20.16 million year-over-year [2] - Ponce Financial has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise of +177.78% in the previous quarter indicates strong performance relative to expectations [1] - The current consensus EPS estimate for the upcoming quarter is $0.19, with projected revenues of $26.5 million, while the estimate for the current fiscal year is $0.79 on revenues of $103.5 million [7] Stock Performance and Outlook - Ponce Financial shares have increased approximately 5.5% year-to-date, compared to an 8.2% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Industry Context - The Financial - Miscellaneous Services industry, to which Ponce Financial belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and earnings estimate revisions, which could impact Ponce Financial's stock performance [5]

Core Viewpoint - Investors are expected to focus on Altimmune's progress with its lead pipeline candidate, pemvidutide, during the second-quarter 2025 results announcement, as the company currently lacks a marketed drug and is projected to report a loss of 32 cents per share [1][10]. Group 1: Pipeline Candidate and Clinical Trials - Pemvidutide is a novel, peptide-based GLP-1/glucagon dual receptor agonist being developed for obesity, metabolic dysfunction-associated steatohepatitis (MASH), alcohol liver disease (ALD), and alcohol use disorder (AUD) [2]. - The phase IIb IMPACT study showed that at 24 weeks, 59.1% and 52.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg achieved MASH resolution without worsening fibrosis, compared to 19.1% with placebo [3]. - Fibrosis improvement without worsening MASH was observed in 31.8% and 34.5% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, versus 25.9% with placebo, although these differences were not statistically significant [4]. Group 2: Weight Loss and Safety Profile - Participants receiving pemvidutide experienced an average weight loss of 5% with the 1.2 mg dose and 6.2% with the 1.8 mg dose, compared to 1% in the placebo group at 24 weeks, indicating a favorable weight loss profile [5]. - Treatment with pemvidutide was generally safe and well-tolerated, which is a positive aspect for its future development [5]. Group 3: Market Performance and Future Expectations - Year to date, Altimmune's shares have declined by 43%, contrasting with a 7.2% increase in the industry [5]. - The company has initiated two separate phase II studies for pemvidutide targeting AUD and ALD, with further updates expected during the upcoming earnings call [6][7]. - Operating expenses are anticipated to have decreased in the upcoming quarter due to the timing of clinical study costs [7]. Group 4: Earnings Surprise History - Altimmune has a mixed earnings surprise history, having beaten estimates in three of the last four quarters, with an average surprise of 9.21% [8]. - In the last reported quarter, the company posted an earnings surprise of 25.71% [8].

Core Insights - Newmont Corporation reported a revenue of $5.32 billion for the quarter ended June 2025, marking a 20.8% increase year-over-year and a surprise of +16.03% over the Zacks Consensus Estimate of $4.58 billion [1] - The earnings per share (EPS) for the quarter was $1.43, significantly higher than the $0.72 reported in the same quarter last year, resulting in an EPS surprise of +37.5% compared to the consensus estimate of $1.04 [1] Financial Performance Metrics - Newmont's stock has returned +5.8% over the past month, slightly outperforming the Zacks S&P 500 composite's +5.7% change, and currently holds a Zacks Rank 2 (Buy) [3] - Attributable Gold Production from Yanacocha was 131.00 Koz, exceeding the two-analyst average estimate of 112.26 Koz [4] - Consolidated silver production was reported at 8,000.00 Koz, surpassing the average estimate of 7,064.04 Koz [4] Geographic Revenue Breakdown - Revenue from Nevada Gold Mines was $783 million, exceeding the estimated $747.19 million, representing a +39.1% change year-over-year [4] - Peñasquito generated $815 million in revenue, significantly higher than the estimated $699.12 million, reflecting a +125.8% year-over-year increase [4] - Merian's revenue was reported at $223 million, compared to the average estimate of $153.38 million, indicating a +114.4% change year-over-year [4] - Cerro Negro's revenue reached $112 million, surpassing the estimated $92.4 million, with a +12% change year-over-year [4] - Yanacocha's revenue was $446 million, exceeding the average estimate of $244.48 million, representing a remarkable +237.9% change year-over-year [4] - Lihir's revenue was $517 million, compared to the average estimate of $478.17 million [4] - Tanami's revenue was $297 million, exceeding the estimated $262.73 million, with a +21.7% change year-over-year [4] - Ahafo generated $657 million in revenue, surpassing the average estimate of $528.69 million, reflecting a +149.8% year-over-year change [4]